289 filings
DEF 14A
VSTM
Verastem Inc
Definitive proxy
12 Apr 24
4:05pm
8-K
VSTM
Verastem Inc
9 Apr 24
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
5:10pm
S-8
VSTM
Verastem Inc
14 Mar 24
Registration of securities for employees
5:14pm
10-K
2023 FY
VSTM
Verastem Inc
Annual report
14 Mar 24
4:55pm
SC TO-I/A
VSTM
Verastem Inc
11 Mar 24
Issuer tender offer statement (amended)
5:07pm
SC TO-I
e9swg006mi0vbax
8 Feb 24
Issuer tender offer statement
4:22pm
8-K
7lyro6b39
29 Jan 24
Regulation FD Disclosure
4:01pm
8-K
0gd 503ps
19 Jan 24
Submission of Matters to a Vote of Security Holders
7:54am
8-K
ffqr1b
8 Jan 24
Entry into a Material Definitive Agreement
4:02pm
EFFECT
gjwu8h kr
21 Nov 23
Notice of effectiveness
12:15am
CORRESP
nwj28v
16 Nov 23
Correspondence with SEC
12:00am
UPLOAD
xzv919p
14 Nov 23
Letter from SEC
12:00am
8-K
m3g1yoc g8lq
27 Oct 23
Departure of Directors or Certain Officers
4:41pm
8-K
jshhwqw b4t4tyjw
28 Sep 23
Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit
2:27pm
8-K
dqjnv bmkcc
12 Sep 23
Corporate Presentation September 2023
4:08pm